Castle Biosciences, Inc. raised earnings guidance for the Full Year 2023. For the period, the Company anticipates generating at least $200 million in total revenue compared to the previously provided guidance of at least $180 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.03 USD | -1.03% | -4.87% | +6.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.72% | 642M | |
-5.12% | 8.16B | |
+8.00% | 5.82B | |
+31.71% | 5.72B | |
-12.56% | 4.01B | |
+12.16% | 2.75B | |
-59.74% | 2.66B | |
-5.70% | 2.39B | |
+16.51% | 2.05B | |
-7.86% | 1.82B |
- Stock Market
- Equities
- CSTL Stock
- News Castle Biosciences, Inc.
- Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023